

David J. Pinsky, et al. Serial No.: 08/721,447 Filed: September 27, 1996 Page 2

--48. The method of claim 48, wherein the sufficient amount comprises 300 $\mu g/kg$.--

1 49.

The method of claim 46, wherein the pharmaceutically acceptable form comprises chemically inactivated Factor IXa and a pharmaceutically acceptable carrier.--

- --50. The method of claim 49, wherein the carrier comprises an aerosol, intravenous, oral or topical carrier.--
- --51. The method of claim 46, wherein the subject is a mammal.-
- --52. The method of claim 51, wherein the mammal is a human.--
- --53. The method of claim 46, wherein the ischemic disorder comprises a peripheral vascular disorder, a pulmonary embolus, a venous thrombosis, a myocardial infarction, a transient ischemic attack, unstable angina, a reversible ischemic neurological deficit, sickle cell anemia or a stroke disorder.--
- --54. The method of claim 46, wherein the subject is undergoing heart surgery, lung surgery, spinal surgery, brain surgery, vascular surgery, abdominal surgery, or organ transplantation surgery.--
- --55. The method of claim 54, wherein the organ transplantation surgery comprises heart, lung, pancreas or liver transplantation surgery.--

1